Safety signal watch

Public safety surveillance, contextualized.

FDA Drug Safety Communications, openFDA enforcement records (recalls), DailyMed label-change watch, and significance-filtered Open Targets pharmacovigilance — formatted for research screening, never for treatment decisions.

Read this before using any safety card. Safety leads with verified, dated sources: FDA Drug Safety Communications, openFDA Drug Enforcement (recalls), and DailyMed label changes. Adverse-event data (FAERS, Open Targets PV) is shown only as a significance-filtered target-level signal and is spontaneous-report-derived — it may be incomplete, duplicated, unverified, or influenced by reporting bias, and it cannot establish causation or incidence. Signals are intended for research screening only — not for medical, treatment, or regulatory decisions.

Latest FDA safety alerts

FDA MedWatch + Drug Safety Communications · Last checked moments ago

FDA Drug Safety Communication — labeling update reviewed for a widely prescribed class

Notable

What changed. FDA issued a Drug Safety Communication describing updated labeling language. Why it matters. Labeling changes shift prescriber risk-benefit framing and downstream payer policy.

Source: FDA MedWatch Classification: Drug Safety Communication Event type: Labeling update Date: recent

Official FDA communications. Surfaced for research screening — not medical or treatment decisions.

Track this drug Generate brief

FDA MedWatch alert — new warning posted for a high-utilization product

High Attention

What changed. A MedWatch safety alert posted to FDA's public feed describes a new warning on a high-utilization product. Why it matters. MedWatch alerts on broadly used products typically trigger prescriber and payer review within days.

Source: FDA MedWatch Classification: Safety Alert Event type: New warning Date: recent

FDA safety alerts are official communications; the underlying primary record is authoritative for clinical decisions.

Track this drug Generate brief

Recent drug recalls

openFDA Drug Enforcement · Last checked moments ago

openFDA Drug Enforcement — Class II recall posted

High Attention

What changed. A Class II recall covering multiple lots was entered into openFDA enforcement records. Why it matters. Class II indicates temporary or reversible health consequences are possible; supply chains and prescribers track these closely.

Source: openFDA Drug Enforcement Classification: Class II Event type: Recall Date: recent

openFDA enforcement records reflect FDA-published recall classifications. Always consult the FDA primary record for full scope and remediation.

Track this drug Generate brief

openFDA Drug Enforcement — Class III recall posted

Monitor

What changed. Class III enforcement record posted covering a specific lot. Why it matters. Class III indicates use is unlikely to cause adverse health consequences; tracked to detect patterns across manufacturers.

Source: openFDA Drug Enforcement Classification: Class III Event type: Recall Date: recent

Class III recall data is informational only; the FDA primary record is authoritative.

Track this drug Generate brief

What you unlock with paid tiers

Pro · $199/mo

Label-change watch & target-level PV signals

DailyMed label-change watch, Open Targets significance-filtered pharmacovigilance signals at the target level, per-drug watchlist alerts, AI-generated daily briefs, PDF and CSV export.

Unlock Pro

Analyst Desk · $399/mo

Sponsor-level safety convergence

Correlate FDA actions with sponsor 8-K language, monitor patent timelines and IP exposure tied to safety-flagged programs, watch wire feeds for sponsor responses.

Unlock Analyst Desk

Research Team · $699/mo

WHO VigiAccess & ex-U.S. pharmacovigilance

Global pharmacovigilance via WHO VigiAccess, NICE and PMDA decision tracking, disease-area dashboards, Evidence Room exports.

Unlock Research Team